Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Harnessing CD8 T cell responses using PD-1–IL-2 combination therapy

Trends in cancer(2023)10.1016/j.trecan.2023.11.008Source: DataRank Database

Harnessing CD8 T cell responses using PD-1–IL-2 combination therapy is a research paper published in Trends in cancer (2023). On theSindex it has a DataRank of 0. It has been cited 50 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access50 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 5.80)OA: greenTopics (22)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Suresh S. Ramalingam ORCID,Rafi Ahmed ORCID,Masao Hashimoto ORCID

Live enrichment

PubMed:38129234 OpenAlex:https://openalex.org/W4389986291

NCI

Grant: P50CA217691

NIAID

Grant: R01AI030048

FWCI

5.80

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11006586/pdf/nihms-1948637.pdf

publisherhttps://api.elsevier.com/content/article/PII:S240580332300239X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S240580332300239X?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11006586

Fields of Study

CAR-T cell therapy researchImmune Cell Function and InteractionCancer Immunotherapy and Biomarkers

MeSH Terms

Cell DifferentiationHumansInterleukin-2NeoplasmsCD8-Positive T-LymphocytesProgrammed Cell Death 1 Receptor

Keywords

Cytotoxic T cellCD8T cellCancer researchCell therapyImmunologyInterleukin 2BiologyStem cellChemistryCell biologyImmune systemBiochemistry

Sustainable Development Goals

SDG 0: Good health and well-being

Related Papers (10)

Opposing Roles of Type I Interferons in Cancer Immunity

N/A

5.7DataRank · unranked

Annual Review of Pathology Mechanisms of Disease(2020)

co-cited

10.1146/annurev-pathol-031920-093932

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist

N/A

0.598DataRank · unranked

Journal for ImmunoTherapy of Cancer(2020)

co-cited

10.1136/jitc-2019-000493

Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation

N/A

0.827DataRank · unranked

Nature Immunology(2021)

co-cited

10.1038/s41590-021-00975-5

Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells

Cell(2021)

co-cited

10.1016/j.cell.2021.01.018

An engineered IL-2 partial agonist promotes CD8+ T cell stemness

N/A

0.781DataRank · unranked

Nature(2021)

co-cited

10.1038/s41586-021-03861-0

NHS-IL12, a Tumor-Targeting Immunocytokine

N/A

0.578DataRank · unranked

ImmunoTargets and Therapy(2021)

co-cited

10.2147/itt.s306150

Phase I/II trial of intratumoral administration of hu14.18-IL2, with local radiation, nivolumab, and ipilimumab in subjects with advanced melanoma.

N/A

0.165DataRank · unranked

Journal of Clinical Oncology(2021)

co-cited

10.1200/jco.2021.39.15_suppl.tps9591

CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor

Immunity(2022)

co-cited

10.1016/j.immuni.2022.12.002

PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program

N/A

0.868DataRank · unranked

Nature(2022)

co-cited

10.1038/s41586-022-05257-0

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells

N/A

0.845DataRank · unranked

Nature(2022)

co-cited

10.1038/s41586-022-05192-0